File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.rmed.2013.06.012
- Scopus: eid_2-s2.0-84883050127
- PMID: 23835189
- WOS: WOS:000330271600018
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Effect of therapeutic arsenic exposure on pulmonary function
Title | Effect of therapeutic arsenic exposure on pulmonary function |
---|---|
Authors | |
Keywords | Arsenic trioxide Clara cell protein Leukaemia Lung function |
Issue Date | 2013 |
Publisher | Elsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/rmed |
Citation | Respiratory Medicine, 2013, v. 107 n. 9, p. 1423-1430 How to Cite? |
Abstract | AIM: Arsenic-contaminated drinking water has been associated with respiratory diseases and lung function impairment. Oral arsenic trioxide (ATO) is a standard treatment for acute promyelocytic leukaemia. This study aimed to explore the effect of therapeutic exposure to arsenic on lung function. PATIENTS AND METHOD: This was a case-control cross-sectional study on patients with haematological malignancies with or without exposure to ATO. Full lung function tests and serum Clara cell protein 16 (CC16) were measured. RESULTS: There were 57 cases (arsenic exposed) and 57 matched controls (arsenic non-exposed) recruited. Among cases, the median duration of ATO exposure was 519 (194-1259) days. The mean FEV(1)/FVC ratio, FEV(1) (% predicted), and RV/TLC (%), as well as % subjects with FEV(1)/FVC below lower limits of normal (LLN), were similar in the two groups with or without arsenic exposure. However the mean TLC (% predicted) and DLCO/VA were significantly higher in arsenic-exposed versus non-exposed group (p = 0.01 and p = 0.008 respectively). There were mildly reduced FEV(1)/FVC ratio and FEF(25-75) (% predicted), largely within normal limits, among high level arsenic exposure compared with non-exposure (p = 0.01 and p = 0.05 respectively). Serum CC16 was comparable among both arsenic exposed and non-exposed groups. CONCLUSION: Therapeutic use of oral ATO for a median of around 1.5 years was not associated with clinically significant lung function impairment. |
Persistent Identifier | http://hdl.handle.net/10722/194964 |
ISSN | 2023 Impact Factor: 3.5 2023 SCImago Journal Rankings: 1.180 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ho, JCM | - |
dc.contributor.author | Au, WY | - |
dc.contributor.author | Han, L | - |
dc.contributor.author | Kwong, YL | - |
dc.contributor.author | Ip, MSM | - |
dc.date.accessioned | 2014-02-21T06:41:14Z | - |
dc.date.available | 2014-02-21T06:41:14Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | Respiratory Medicine, 2013, v. 107 n. 9, p. 1423-1430 | - |
dc.identifier.issn | 0954-6111 | - |
dc.identifier.uri | http://hdl.handle.net/10722/194964 | - |
dc.description.abstract | AIM: Arsenic-contaminated drinking water has been associated with respiratory diseases and lung function impairment. Oral arsenic trioxide (ATO) is a standard treatment for acute promyelocytic leukaemia. This study aimed to explore the effect of therapeutic exposure to arsenic on lung function. PATIENTS AND METHOD: This was a case-control cross-sectional study on patients with haematological malignancies with or without exposure to ATO. Full lung function tests and serum Clara cell protein 16 (CC16) were measured. RESULTS: There were 57 cases (arsenic exposed) and 57 matched controls (arsenic non-exposed) recruited. Among cases, the median duration of ATO exposure was 519 (194-1259) days. The mean FEV(1)/FVC ratio, FEV(1) (% predicted), and RV/TLC (%), as well as % subjects with FEV(1)/FVC below lower limits of normal (LLN), were similar in the two groups with or without arsenic exposure. However the mean TLC (% predicted) and DLCO/VA were significantly higher in arsenic-exposed versus non-exposed group (p = 0.01 and p = 0.008 respectively). There were mildly reduced FEV(1)/FVC ratio and FEF(25-75) (% predicted), largely within normal limits, among high level arsenic exposure compared with non-exposure (p = 0.01 and p = 0.05 respectively). Serum CC16 was comparable among both arsenic exposed and non-exposed groups. CONCLUSION: Therapeutic use of oral ATO for a median of around 1.5 years was not associated with clinically significant lung function impairment. | - |
dc.language | eng | - |
dc.publisher | Elsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/rmed | - |
dc.relation.ispartof | Respiratory Medicine | - |
dc.subject | Arsenic trioxide | - |
dc.subject | Clara cell protein | - |
dc.subject | Leukaemia | - |
dc.subject | Lung function | - |
dc.subject.mesh | Antineoplastic Agents - adverse effects | - |
dc.subject.mesh | Arsenicals - adverse effects | - |
dc.subject.mesh | Leukemia, Promyelocytic, Acute - drug therapy - physiopathology | - |
dc.subject.mesh | Lung Diseases - chemically induced - physiopathology | - |
dc.subject.mesh | Oxides - adverse effects | - |
dc.title | Effect of therapeutic arsenic exposure on pulmonary function | - |
dc.type | Article | - |
dc.identifier.email | Ho, JCM: jhocm@hku.hk | - |
dc.identifier.email | Au, WY: auwing@hkucc.hku.hk | - |
dc.identifier.email | Kwong, YL: ylkwong@hku.hk | - |
dc.identifier.email | Ip, MSM: msmip@hku.hk | - |
dc.identifier.authority | Ho, JCM=rp00258 | - |
dc.identifier.authority | Kwong, YL=rp00358 | - |
dc.identifier.authority | Ip, MSM=rp00347 | - |
dc.identifier.doi | 10.1016/j.rmed.2013.06.012 | - |
dc.identifier.pmid | 23835189 | - |
dc.identifier.scopus | eid_2-s2.0-84883050127 | - |
dc.identifier.hkuros | 228084 | - |
dc.identifier.hkuros | 287784 | - |
dc.identifier.hkuros | 287783 | - |
dc.identifier.volume | 107 | - |
dc.identifier.issue | 9 | - |
dc.identifier.spage | 1423 | - |
dc.identifier.epage | 1430 | - |
dc.identifier.isi | WOS:000330271600018 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 0954-6111 | - |